ProStrakan Secures Offer From Japan's Kyowa Hakko, But Analysts Say Too Low
This article was originally published in The Pink Sheet Daily
Executive Summary
Kyowa Hakko Kirin's offer to buy U.K.-based specialty pharma ProStrakan values the company lower than other similar deals.
You may also be interested in...
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
Abstral Approval May Fetch ProStrakan The Valuation It's After
A second U.S. product approval in two weeks, plus a partner-driven re-financing, means the price of ProStrakan just went up.